ERBB2 and breast carcinoma: The ZEST trial (NCT04915755), started in 2021, is a randomised phase III study that has been enrolling patients with localised breast cancer that is either triple negative or HR +/HER2- with a known BRCA tissue mutation (irrespective of BRCA status).